MX2022001151A - Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. - Google Patents

Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.

Info

Publication number
MX2022001151A
MX2022001151A MX2022001151A MX2022001151A MX2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A
Authority
MX
Mexico
Prior art keywords
methods
deuterated
pathway
inhibitors
map kinase
Prior art date
Application number
MX2022001151A
Other languages
English (en)
Spanish (es)
Inventor
David Randolph Anderson
Gary Anthony Decrescenzo
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of MX2022001151A publication Critical patent/MX2022001151A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022001151A 2019-07-31 2020-07-31 Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. MX2022001151A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881026P 2019-07-31 2019-07-31
PCT/US2020/044558 WO2021022186A1 (en) 2019-07-31 2020-07-31 Deuterated mk2 pathway inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
MX2022001151A true MX2022001151A (es) 2022-02-22

Family

ID=74228512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001151A MX2022001151A (es) 2019-07-31 2020-07-31 Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.

Country Status (12)

Country Link
US (1) US12403141B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003344A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022542434A (cg-RX-API-DMAC7.html)
KR (1) KR20220041180A (cg-RX-API-DMAC7.html)
CN (1) CN114206339A (cg-RX-API-DMAC7.html)
AU (1) AU2020319879A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001324A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149304A1 (cg-RX-API-DMAC7.html)
IL (1) IL290045A (cg-RX-API-DMAC7.html)
MX (1) MX2022001151A (cg-RX-API-DMAC7.html)
PH (1) PH12022550029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021022186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
WO2022212489A1 (en) 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
US11685719B2 (en) 2021-07-09 2023-06-27 Xinthera, Inc. Pyridinone MK2 inhibitors and uses thereof
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
CN116444492B (zh) * 2021-12-29 2026-03-03 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274B (zh) * 2022-01-06 2025-11-11 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
CN119384410B (zh) * 2022-03-03 2026-06-12 深圳信立泰药业股份有限公司 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
US20260217652A1 (en) * 2023-01-13 2026-07-30 Shanghai Meiyue Biotech Development Co., Ltd. Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof
JP2026504073A (ja) * 2023-01-13 2026-02-03 プールベグ ファーマ(ユーケー) リミテッド がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
CA2763565A1 (en) * 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
US9359300B2 (en) * 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
KR102313515B1 (ko) 2013-06-07 2021-10-14 어클라리스 쎄라퓨틱스, 인코포레이티드 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
AU2017250086A1 (en) * 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CN111727042A (zh) * 2017-12-06 2020-09-29 仁新医药私人有限公司 微管蛋白抑制剂
WO2021178449A1 (en) 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
IL290045A (en) 2022-03-01
EP4003344A1 (en) 2022-06-01
CA3149304A1 (en) 2021-02-04
EP4003344A4 (en) 2023-07-26
BR112022001324A2 (pt) 2022-03-22
JP2022542434A (ja) 2022-10-03
KR20220041180A (ko) 2022-03-31
US20220288070A1 (en) 2022-09-15
US12403141B2 (en) 2025-09-02
PH12022550029A1 (en) 2023-02-27
AU2020319879A1 (en) 2022-02-03
CN114206339A (zh) 2022-03-18
WO2021022186A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
PH12022550029A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2022003782A2 (es) Inhibidores de kras g12d
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2022000711A (es) Inhibidores de parp1.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
UY27729A1 (es) Inhibidores de quinasas.
MX390625B (es) Inhibidores selectivos de jak1.
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2021000648A1 (es) Piridazinonas y sus métodos de uso
ECSP109953A (es) Derivados de piridazinona
ECSP034750A (es) Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы